Article Contents ::
Details About Generic Salt :: Mitomycin
Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents
| 18A. ANTI-NEOPLASTIC AGENTS in 18. ANTI-NEOPLASTIC AGENTS |
| MITOMYCIN |
| ANTIBIOTIC | ANTI-NEOPLASTIC |
| PK: D: 22 L/m2 (Vd) M: Hepatic E: Urine (<10% as unchanged drug) |
|
Indications & Dose: ADENOCARCINOMA OF STOMACH/PANCREAS Combination therapy IV Adult 10mg/m2 as inf over 15-30min q6-8wk | Mono therapy IV Adult 20mg/m2 as inf over 15-30min q6-8wk |
| Contra: Hypersensitivity, thrombocytopenia, coagulation disorders, increased bleeding tendency, renal impairment if SeCr >1.7 mg/dL, acute infect
Precautions: Children, debilitated patients, depressed bone marrow from radiotherapy/therapy with other anti-neoplastics ADR: Serious: Profound leucopenia & thrombocytopenia, delayed cumulative bone-marrow suppression, renal damage, pulmonary reactions, hemolytic-uremic syndrome, GI toxicity, cardiotoxicity, local tissue necrosis/ulceration/cellulitis, CHF, interstitial pneumonitis, Others: dyspnea & cough, nail banding/discoloration, nausea, vomiting, anorexia, anemia, rash, paresthesia, dermatitis, alopecia, fever, malaise DDI: Serious Fluorouracil (rarely)leads to serious & potentially life-threatening intravascular hemolysis & renal failure (long-term use), Tamoxifen causes hemolytic anemia, thrombocytopenia & renal impairment, leading to potentially fatal hemolytic uremic syndrome, Doxorubicin increases the incidence of cardiotoxicity, Vindesine/Vinblastine/Vinorelbine leads to a syndrome of acute pulmonary toxicity (severe shortness of breath) Monitor: Platelet count, CBC with differential, Hb, prothrombin time, renal & pulmonary function tests |